image dons

I make a donation


To compare the effects of firibastat to those of ramipril to prevent left ventricular dysfunction after acute myocardial infarction


logo étude


To compare the effects of twice daily oral administration of firibastat to those of oral administration of ramipril on the change from Baseline in left ventricular ejection fraction after an acute anterior myocardial infarction.

date de réalisation


nombre de patients


nombre de centres participants

International multicentric trial

type de financement

Private (Quantum Genomics)



Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction (QUORUM)

Study Description

This is a multicenter, randomized, double-blind, active-controlled, dose-titrating phase 2 study to evaluate the safety and efficacy of firibastat administered orally BID (2 daily doses) versus ramipril administered orally BID over 12 weeks after acute anterior MI.
Subjects will be followed for 12 weeks (over 4 study visits). A total of 294 male and female subjects with a diagnosis of first acute anterior MI will be randomized. The subjects will need to have a primary percutaneous coronary intervention (PCI) of the index MI related artery within 24 hours after MI.
At Inclusion Visit (Visit 2 [within 72 hours after acute MI]), subjects will be randomly assigned to 1 of the following 3 treatment groups in a 1:1:1 ratio:

  • Group 1: Subjects will receive 50 mg firibastat BID for 2 weeks and then 100 mg BID for 10 weeks
  • Group 2: Subjects will receive 250 mg firibastat BID for 2 weeks and then 500 mg BID for 10 weeks
  • Group 3: Subjects will receive 2.5 mg ramipril BID for 2 weeks and then 5 mg BID for 10 weeks


Autres études



En cours

Impact of genetics on occuring of coronary diseases in young patients and the pharmacogenetic of clopidogrel and its impact on the prognosis of patients having had angioplasty


En cours

A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....


En cours

To assess if flecainide is more efficient than standard of care (control group) to prevent AF occurrence during the 3 months after PFO closure.